Journal of Clinical Oncology · 2000 · 57 citations · 25 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyClinical PharmacologyChemotherapy Toxicity ManagementDose Adjustment In OncologyOncology PharmacologyPharmacokinetics In Children With CancerPharmacokinetics Of Anticancer DrugsToxicity ManagementChemotherapy Dose-limiting ToxicityChemotherapy-induced Gastrointestinal ToxicityClinical Pharmacology EvidenceDose-limiting Toxicity AssessmentIrinotecan-based TherapyRecommended Phase Ii DoseSteady-state Plasma ConcentrationTherapeutic Steady-state Concentration
PURPOSE: We conducted a phase I and pharmacologic study of a weekly 96-hour infusion of irinotecan to determine the maximum-tolerated dose, define the toxicity profile, and characterize the clinical pharmacology of irinotecan and its metabolites. PATIENTS AND METHODS: In 26 adult patients with solid tumors, the duration and dose rate of infusion were escalated in new patients until toxicity was observed. RESULTS: In 11 patients who were treated with irinotecan at 12.5 mg/m(2)/d for 4 days weekly for 2 of 3 weeks, dose-limiting grade 3 diarrhea occurred in three patients and grade 3 thrombocytopenia occurred in two patients. The recommended phase II dose is 10 mg/m(2)/d for 4 days given weekly for 2 of 3 weeks. At this dose, the steady-state plasma concentration (Css) of total SN-38 (the active metabolite of irinotecan) was 6.42 +/- 1.10 nmol/L, and the Css of total irinotecan was 28.60 +/- 17.78 nmol/L. No patient experienced grade 3 or 4 neutropenia during any cycle. All other toxicities were mild to moderate. The systemic exposure to SN-38 relative to irinotecan was greater than anticipated, with a molar ratio of the area under the concentration curve (AUC) of SN-38 to irinotecan of 0.24 +/- 0.08. One objective response lasting 12 months in duration was observed in a patient with metastatic colon cancer. CONCLUSION: The recommended phase II dose of irinotecan of 10 mg/m(2)/d for 4 days weekly for 2 of 3 weeks was extremely well tolerated. Further efficacy testing of this pharmacologic strategy of administering intermittent low doses of irinotecan is warranted.
25
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
E Gupta, Timothy M. Lestingi, Rosemarie Mick et al. · PubMed · 1994 · 506 citations
Philippe Rougier, R. Bugat, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 1997 · 433 citations
Medicine, Oncology, Pharmacology +14
Peter J. Houghton, Pamela J. Cheshire, James D. Hallman et al. · Cancer Chemotherapy and Pharmacology · 1995 · 407 citations
Medicine, Oncology, Pharmacology +12